国产药再攻破一大疾病领域!人福药业米拉贝隆缓释片仿制申请获受理,国产替代逻辑再验证

Ofweek维科网
Feb 10

一则上市申请受理公告,让沉寂不久的泌尿领域仿制药赛道泛起涟漪。2月7日,CDE官网显示,武汉人福药业按化药注册分类4类申报的 米拉贝隆缓释片 上市申请获受理。据摩熵医药数据库显示,米拉贝隆 在2024年全球销售额已超11亿美元,成为膀胱过度活动症(OAB)治疗领域当之无愧的重磅品种。在全球创新药研发风险攀升、普通仿制药利润趋薄的当下,这样一款兼具新机制、高增长、医保覆盖的品种,为何引来多家药企扎堆...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10